Floatz logo

Setmelanotide

PCSK1 Deficiency Obesity

Rhythm Pharmaceuticals, Inc.protein_peptidePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the PCSK1 Deficiency Obesity cohort.

Asset / SponsorPhaseRating
lb54640
LG Chem
Phase 2CCC
Dccr
Soleno Therapeutics, Inc.
Phase 2CCC

Same molecule, other indications

Setmelanotide is also rated in:

Bardet-Biedl syndromeDormant
A
Indicative ·
81 / 100
View asset →
Alstrom syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
inherited obesityDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →